within Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01D_CytotoxicAntibioticsAndRelatedSubstances.L01DB08_Pirarubicin;

model Pirarubicin
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C(
    weight = 70,
    F = 1,
    Cl = 9.916666666666668e-06,
    adminDuration = 600,
    adminMass = 30 / 1000000,
    adminCount = 1,
    Vd = 0.022699999999999998,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    Vdp = 0.0121,
    k12 = 1.0666666666666666e-05,
    k21 = 1.0666666666666666e-05);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Pirarubicin</td></tr><tr><td>ATC code:</td><td>L01DB08</td></tr><td>route:</td><td>intravenous</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>30</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>22.7</td><td>L</td></tr>
    <tr><td>clearance:</td><td>35.7</td><td>L/h/m2</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Pirarubicin is an anthracycline antineoplastic agent structurally related to doxorubicin, primarily used for the treatment of various cancers, including breast, bladder, and lung cancers. It is typically administered intravenously or via intravesical instillation. Pirarubicin is approved in certain countries, such as Japan, but is not globally approved.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for adult cancer patients (various types), after intravenous infusion.</p><h4>References</h4><ol></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.L.L01DB08 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Pirarubicin;
